Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience.
ICD
cardiac arrest
children
hypertrophic cardiomyopathy
medical management
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
24
12
2019
revised:
14
05
2020
accepted:
17
06
2020
pubmed:
19
7
2020
medline:
12
8
2021
entrez:
19
7
2020
Statut:
ppublish
Résumé
Hypertrophic cardiomyopathy (HCM) is the second most common pediatric cardiomyopathy. Although there is a large body of literature about HCM in adults, there is limited information on HCM in childhood. We evaluated various aspects of pediatric HCM patients treated at our center. We identified 152 pediatric patients with HCM between October 2011 and October 2019. Clinical history, invasive (ICD, pacemaker, electrophysiologic study, catheter ablation therapy) and non-invasive (ECG, holter moniterization, echocardiography, cardiac MR, genetic study, medicam treatment) data were collected and evaluated. The mean ± standard deviation age of patients was 8.9 ± 5.7 years (1 month-18 years) and 67.8% were male. The most frequent clinical symptoms were murmur and palpitations. Three cases (2%) had aborted sudden death as the first manifestation of HCM. Of these patients, 120 (78.9%) had non-syndromic HCM and 32 (27.2%) had syndromic HCM. Asymmetric septal hypertrophy was common (48.3%) in the non-syndromic group, whereas concentric hypertrophy was common (56.2%) in syndromic group. Left ventricular outflow tract obstruction (LVOTO) occurred in 39 (25.6%) patients. Nine (5.9%) patients underwent electrophysiologic study and/or ablation and 16 patients underwent surgical intervention. Implantable cardioverter defibrillator (ICD) insertion was performed in 38 patients (26 transvenous, 12 epicardial). ICDs were inserted in three (7.9%) patients for secondary prevention; in the remaining patients (92.1%) the devices were placed for primary prevention. Mean SD follow-up time was 27.1 ± 22 months. Five (3.3%) patients died during the follow-up. No patient had heart transplantation or a long-term assistive device. The etiology of HCM is heterogeneous and present at any age. It is important to determine the timing of surgery and potential risks for sudden cardiac arrest. As most cases of HCM are familial, evaluation of family members at risk should be a routine component of clinical management.
Sections du résumé
BACKGROUND
BACKGROUND
Hypertrophic cardiomyopathy (HCM) is the second most common pediatric cardiomyopathy. Although there is a large body of literature about HCM in adults, there is limited information on HCM in childhood. We evaluated various aspects of pediatric HCM patients treated at our center.
METHODS
METHODS
We identified 152 pediatric patients with HCM between October 2011 and October 2019. Clinical history, invasive (ICD, pacemaker, electrophysiologic study, catheter ablation therapy) and non-invasive (ECG, holter moniterization, echocardiography, cardiac MR, genetic study, medicam treatment) data were collected and evaluated.
RESULTS
RESULTS
The mean ± standard deviation age of patients was 8.9 ± 5.7 years (1 month-18 years) and 67.8% were male. The most frequent clinical symptoms were murmur and palpitations. Three cases (2%) had aborted sudden death as the first manifestation of HCM. Of these patients, 120 (78.9%) had non-syndromic HCM and 32 (27.2%) had syndromic HCM. Asymmetric septal hypertrophy was common (48.3%) in the non-syndromic group, whereas concentric hypertrophy was common (56.2%) in syndromic group. Left ventricular outflow tract obstruction (LVOTO) occurred in 39 (25.6%) patients. Nine (5.9%) patients underwent electrophysiologic study and/or ablation and 16 patients underwent surgical intervention. Implantable cardioverter defibrillator (ICD) insertion was performed in 38 patients (26 transvenous, 12 epicardial). ICDs were inserted in three (7.9%) patients for secondary prevention; in the remaining patients (92.1%) the devices were placed for primary prevention. Mean SD follow-up time was 27.1 ± 22 months. Five (3.3%) patients died during the follow-up. No patient had heart transplantation or a long-term assistive device.
CONCLUSION
CONCLUSIONS
The etiology of HCM is heterogeneous and present at any age. It is important to determine the timing of surgery and potential risks for sudden cardiac arrest. As most cases of HCM are familial, evaluation of family members at risk should be a routine component of clinical management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-45Informations de copyright
© 2020 Japan Pediatric Society.
Références
Lipshultz SE, Sleeper LA, Towbin JA et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 2003; 348: 1647-55 e55.
Nugent AW, Daubeney PE, Chondros P et al. The epidemiology of childhood cardiomyopathy in Australia. N. Engl. J. Med. 2003; 348: 1639 e46.
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;119:1085 e92.
Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113 (14): 1807-16.
Maskatia SA. Hypertrophic cardiomyopathy: infants, children, and adolescents. Congenit. Heart Dis. 2012;7(1):84-92.
Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM et al.l. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 2017; 24 (11): 1220-30.
Gersh BJ, Maron BJ, Bonow RO et al. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy : a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2011; 2011 (58): e212-e60.
Elliott PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014;35(39):2733-79.
Nugent AW, Daubeney PE, Chondros P et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112: 1332-8.
Colan SD, Lipshultz SE, Lowe AM et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Paediatric Cardiomyopathy Registry. Circulation 2007; 115: 773-81.
Lipshultz SE, Orav EJ, Wilkinson JD et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Paediatric Cardiomyopathy Registry. Lancet 2013; 382: 1889-97.
Maron BJ, Tajik AJ, Ruttenberg HD et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982; 65: 7e17.
Ostman-Smith I, Wettrell G, Keeton B et al. Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. Eur. Heart J. 2008; 29: 1160 e7.
Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart 2012; 98(14):1044-54.
Valente AM, Lakdawala NK, Powell AJ et al. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Send to Circ. Cardiovasc. Genet. 2013; 6 (3): 230-7.
Brothers MB, Oster ME, Ehrlich A, Strieper MJ, Mahle WT. Novel electrocardiographic screening criterion for hypertrophic cardiomyopathy in children. Am. J. Cardiol. 2014; 113 (7): 1246-9.
Spoladore R, Maron MS, D'Amato R, Camici PG. Olivotto I Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur. Heart J. 2012; 33 (14): 1724-33.
Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J. Cardiovasc. Electrophysiol. 2008; 19 (10): 1118-26.
Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr. Clin. North Am. 2004; 51: 1305 e46.
McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996; 94: 467-71.
Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J. Thorac. Cardiovasc. Surg. 1996; 111: 586-94.
Efthimiadis GK, Zegkos T, Meditskou S, Hadjimiltiades S. Perspectives on sudden death prevention in hypertrophic cardiomyopathy. Cardiol. Rev. 2014; 22 (5): 210-6.
Maron BJ, Spirito P, Ackerman MJ et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J. Am. CollCardiol. 2013; 61 (14): 1527-35.
Charron P, Arad M, Arbustini E et al. Genetic counseling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. EurHeart J. 2010; 31: 2715 e26.
Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N. Engl. J. Med. 1986; 315: 610 e14.